Neurology: Clotting and hemostatic activation markers help identify the cause of cryptic stroke

Recently, a study published in Neurology, an authoritative journal of neurology, was published to test the hypothesis that clotting and hemostatic activation markers (MOCHA) help edify the cause of hidden stroke, and the researchers obtained serum index data from 132 patients and followed them up to identify the cause of strokefrom January 1, 2017 to October 31, 2018, patients who met the cryptic embolism (ESUS) criteria received outpatient cardiac monitoring and received MOCHA (serodd-dipolymer, coagulase 1.2 fragments, coagulation enzyme-anticoagulase complex, fibrilline) within 2 weeks of strokeThe predetermined endpoints monitored in routine clinical visits include new atrial fibrillation (AF), malignant tumors, venous thrombosis (VTE), or other determined high coagulation states (HS)132 ESUS patients (with an average age of 64 to 15 years, 61% female and 51% non-white) met the study criteriaDuring the median follow-up of 10 months (7-14 months between quarterbacks), 31 (23%) patients were diagnosed with atrial fibrillation, malignancies, VTE or HS; 0%, p 0.001), VTE (9% vs0%, p.009) or HS (11% vs0%, p.004), but not AF (8% vs9%, p.79)The sensitivity of 4 normal MOCHA and normal left room size (n-30) was 100% to exclude pre-specified endpointsthus shows that MOCHA can be found in short-term follow-up patients with new malignancies, VTE or HS, which can be used directly to assess the potential causes of reticuticent stroke